Table 1
Loss of heterozygosity analysis of the 1p34.1 region in primary hepatocellular carcinomas
| Patient | Age/Sex | Aetiology | Tumour size (cm) | Grading | D1S421 | D1S2802 | D1S451 | D1S2677 | Mutation |
|---|---|---|---|---|---|---|---|---|---|
| *PCR products have also been sequenced. | |||||||||
| Four microsatellite markers from the 1p34.1 region (D1S421, D1S2677, D1S451, and D1S2802), which are located centromeric and telomeric of the PRDX1 gene, were used. | |||||||||
| HBV, hepatitis B virus; HCV, hepatitis C virus; LOH, loss of heterozygosity; ROH, retention of heterozygosity. | |||||||||
| HCC1 | 76/M | HCV, cirrhosis | 4.2 | G1 | NI | ROH | ROH | NI | None* |
| HCC7 | 67/M | No cirrhosis | 17 | G2 | NI | ROH | NI | ROH | None* |
| HCC8 | 55/F | HBV, cirrhosis | 5.5 | G2 | NI | ROH | NI | ROH | None* |
| HCC9 | 51/F | HBV, fibrosis | 2.4 | G3 | NI | ROH | NI | ROH | None* |
| HCC10 | 80/F | HCV, cirrhosis | 4.2 | G2 | ROH | ROH | ROH | ROH | None* |
| HCC11 | 62/M | Haemochromatosis, fibrosis | 10.5 | G2 | ROH | ROH | NI | NI | None |
| HCC12 | 48/M | HCV, cirrhosis | 2.5 | G3 | NI | ROH | NI | ROH | None* |
| HCC13 | 82/M | No cirrhosis | 7.0 | G2 | NI | NI | NI | ROH | None* |
| HCC14 | 69/F | HBV, fibrosis | 8.5 | G2 | NI | ROH | NI | ROH | None |
| HCC15 | 71/M | No cirrhosis | 1.6 | G2 | NI | ROH | NI | NI | None |
| HCC16 | 81/F | No cirrhosis | 18.0 | G1 | ROH | NI | NI | NI | None* |
| HCC17 | 64/M | HBV, cirrhosis | 2.1 | G2 | NI | NI | NI | ROH | None |
| HCC18 | 48/M | HCV, cirrhosis | 13.0 | G2 | ROH | ROH | NI | NI | None |
| HCC19 | 56/M | Alcohol, no cirrhosis | 2.1 | G1 | NI | ROH | ROH | NI | None |
| HCC20 | 49/M | HBV, cirrhosis | 10.0 | G2 | ROH | ROH | ROH | ROH | None |
| HCC21 | 37/F | No cirrhosis | 5.0 | G2 | ROH | ROH | NI | ROH | None |
| HCC22 | 46/M | HCV, cirrhosis | 6.0 | G2 | NI | NI | NI | ROH | None |
| HCC23 | 70/M | HCV, cirrhosis | 2.2 | G1 | NI | ROH | NI | ROH | None* |
| HCC24 | 67/M | cirrhosis | 5.0 | G2 | NI | ROH | NI | ROH | None* |
| HCC25 | 65/F | Alcohol, cirrhosis | 3.8 | G2 | NI | LOH | NI | LOH | None* |
| HCC27 | 36/M | HBV, alcohol, cirrhosis | 8.0 | G3 | ROH | ROH | NI | NI | None |
| HCC28 | 63/M | Alcohol, cirrhosis | 3.5 | G2 | NI | NI | NI | NI | None |
| HCC29 | 56/M | Alcohol, no cirrhosis | 4.0 | G2 | NI | NI | NI | NI | None* |
| HCC30 | 65/F | No cirrhosis | 11.0 | G1 | LOH | LOH | NI | LOH | None* |
| HCC31 | 51/M | HCV, cirrhosis | 2.5 | G2 | NI | ROH | NI | ROH | None* |
| HCC33 | 41/F | Alagille syndrome, cirrhosis | 6.5 | G3 | NI | NI | ROH | ROH | None* |
| HCC34 | 75/M | No cirrhosis | 5.0 | G2 | NI | ROH | ROH | NI | None |
| HCC35 | 23/F | HBV, cirrhosis | 18.0 | G2 | NI | LOH | LOH | NI | None* |
| HCC36 | 57/M | HBV, cirrhosis | 6.5 | G2 | ROH | ROH | NI | ROH | None |
| HCC37 | 61/F | HCV, fibrosis | 4.2 | G2 | NI | ROH | ROH | ROH | None |
| HCC38 | 58/ M | HCV, cirrhosis | 2.9 | G2 | ROH | ROH | NI | NI | None |
| HCC39 | 72/M | Cirrhosis | 6.5 | G2 | ROH | NI | NI | NI | None |
| HCC40 | 56/M | Haemochromatosis, fibrosis | 4.8 | G2 | ROH | NI | NI | NI | None |
| HCC41 | 54/M | HCV, fibrosis | 4.0 | G2 | ROH | ROH | ROH | NI | None |
| HCC42 | 69/M | Cirrhosis | 4.5 | G2 | ROH | ROH | ROH | ROH | None |
| HCC43 | 58/M | Alcohol, cirrhosis | 7.5 | G3 | NI | NI | NI | ROH | None |
